18889881171
Kalkine 0
countryflagUS

Arcutis Biotherapeutics Inc

Healthcare US ARQT

13.79USD
0.03(0.22%)

Last update at 2025-05-22T16:44:00Z

Day Range

13.4913.88
LowHigh

52 Week Range

2.0013.50
LowHigh

Fundamentals

  • Previous Close 13.76
  • Market Cap1472.43M
  • Volume492305
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-179.40800M
  • Revenue TTM138.71M
  • Revenue Per Share TTM1.23
  • Gross Profit TTM 2.93M
  • Diluted EPS TTM-1.67

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -311.45800M -206.35600M -135.67800M -41.99600M -19.25500M
Minority interest - - - - -
Net income -321.28900M -205.90200M -135.67800M -41.99600M -19.25500M
Selling general administrative 122.12M 60.97M 21.34M 6.61M 1.79M
Selling and marketing expenses - - - - -
Gross profit 2.93M - - - -
Reconciled depreciation 0.93M 0.45M 0.12M 0.20M -
Ebit -301.62700M -206.98300M -136.64500M -43.13200M -20.21500M
Ebitda -295.80600M -206.52900M -136.52300M -42.93700M -19.73500M
Depreciation and amortization 5.82M 0.45M 0.12M 0.20M 0.48M
Non operating income net other - 0.17M 0.97M - -
Operating income -301.62700M -206.52900M -136.64500M -43.13200M -19.73500M
Other operating expenses 305.31M 206.53M 136.65M 43.13M 19.73M
Interest expense 15.65M 0.45M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income - - - - -
Net interest income -15.65200M - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 9.83M -0.45400M -0.96700M -1.13600M -0.48000M
Total revenue 3.69M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 304.56M 206.53M 136.65M 43.13M 19.73M
Cost of revenue 0.75M - - - -
Total other income expense net -9.83100M 0.17M 0.97M 1.14M 0.48M
Discontinued operations - - - - -
Net income from continuing ops -311.45800M -206.35600M -135.67800M -41.99600M -19.25500M
Net income applicable to common shares -311.45800M -206.35600M -135.67800M -41.99600M -19.25500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 341.37M 449.27M 408.15M 298.27M 107.01M
Intangible assets 6.44M 7.19M - - -
Earning assets - - - - -
Other current assets 18.70M 10.61M 14.17M 8.38M 5.21M
Total liab 252.70M 239.69M 110.47M 27.65M 172.04M
Total stockholder equity 88.67M 209.58M 297.68M 270.62M -65.02900M
Deferred long term liab - - - - -
Other current liab 33.94M 28.32M 25.54M 15.46M 3.65M
Common stock 0.00900M 0.00600M 0.00500M 0.00400M -166.49100M
Capital stock 0.00900M 0.00600M 0.00500M 0.00400M 0.00000M
Retained earnings -981.90400M -719.76400M -408.30600M -201.95000M -66.27200M
Other liab - - 0.03M 0.08M 0.18M
Good will - - - - -
Other assets - 0.08M 0.08M 0.08M 0.05M
Cash 89.32M 53.64M 96.45M 65.08M 63.34M
Cash and equivalents - - - - -
Total current liabilities 46.67M 37.81M 33.33M 22.60M 5.24M
Current deferred revenue - - - - -
Net debt 116.59M 148.90M -18.89200M -60.11800M -63.02900M
Short term debt 0.73M 0.66M 0.43M - 0.18M
Short long term debt - - - - -
Short long term debt total 205.92M 202.54M 77.56M 4.96M 0.31M
Other stockholder equity 1070.56M 930.42M 706.23M 174.30M -165.24700M
Property plant equipment - 4.60M 2.26M 2.02M 0.49M
Total current assets 330.43M 437.41M 402.77M 292.83M 106.47M
Long term investments - - - - -
Net tangible assets - 202.39M 297.68M 270.62M -65.02900M
Short term investments 183.46M 355.95M 290.61M 219.36M 37.93M
Net receivables 25.81M 8.46M 0.36M 0.51M 0.14M
Long term debt 201.80M 197.77M 72.35M - -
Inventory 13.13M 7.51M 1.18M -0.51000M -
Accounts payable 11.99M 8.83M 7.35M 7.14M 1.41M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00400M -1.08600M -0.25500M -0.00200M -0.00100M
Additional paid in capital - - - - -
Common stock total equity - - 0.00500M 0.00400M -
Preferred stock total equity - - - - -
Retained earnings total equity - - -408.30600M -201.95000M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.60M 0.08M 0.08M 0.08M 0.05M
Deferred long term asset charges - - - - -
Non current assets total 10.93M 11.87M 5.38M 5.44M 0.54M
Capital lease obligations 4.12M 4.77M 5.21M 4.96M 0.31M
Long term debt total - - 72.35M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -87.19900M -74.95800M -181.50300M -26.32500M -11.53200M
Change to liabilities 1.56M 10.71M 17.55M -0.45800M 1.26M
Total cashflows from investing activities -87.19900M -75.95300M -181.82400M -26.32500M -11.53200M
Net borrowings 125.00M 72.35M 73.99M 73.99M 73.99M
Total cash from financing activities 301.80M 281.95M 298.14M 93.10M 61.59M
Change to operating activities 4.23M 3.38M 8.46M -1.04700M 0.84M
Net income -311.45800M -206.35600M -135.67800M -41.99600M -19.25500M
Change in cash -43.11600M 31.37M 3.29M 23.94M 35.98M
Begin period cash flow 97.99M 66.62M 63.34M 39.39M 3.42M
End period cash flow 54.88M 97.99M 66.62M 63.34M 39.39M
Total cash from operating activities -257.71500M -174.62700M -113.03300M -42.83600M -14.08500M
Issuance of capital stock 176.05M 207.49M 297.00M 94.24M 61.21M
Depreciation 0.93M 0.45M 0.12M 0.20M 0.20M
Other cashflows from investing activities - - - -26.03000M -11.53200M
Dividends paid - - - - -
Change to inventory -7.51400M -7.51400M -7.51400M -7.51400M -
Change to account receivables -8.45800M -8.45800M -8.45800M -8.45800M -
Sale purchase of stock 12.47M 0.84M 0.62M 94.50M 61.59M
Other cashflows from financing activities 113.28M 73.61M 0.53M -1.13600M 61.59M
Change to netincome 62.98M 23.89M 7.99M 0.47M 3.06M
Capital expenditures 23.28M 0.99M 0.32M 0.29M 0.29M
Change receivables - - - - -
Cash flows other operating - -6.77700M -3.08500M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 31.37M 3.29M - -
Change in working capital -10.17500M 3.62M 14.13M -1.50500M 2.11M
Stock based compensation 32.68M 23.89M 7.94M 0.82M 0.15M
Other non cash items 30.30M 0.31M 0.33M -0.35400M 2.91M
Free cash flow -280.99800M -175.62200M -113.35400M -43.13100M -14.08500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARQT
Arcutis Biotherapeutics Inc		 0.03 0.22% 13.79 - - 10.62 9.27 9.58 -2.0404
NVO
Novo Nordisk A/S		 -0.155 0.23% 68.05 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.95 1.40% 68.95 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -4.41 1.01% 430.91 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -10.3 1.70% 594.32 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics Inc

3027 Townsgate Road, Westlake Village, CA, United States, 91361

Key Executives

Name Title Year Born
Mr. Todd Franklin Watanabe M.A. Pres, CEO & Director 1968
Dr. Bhaskar Chaudhuri Ph.D. Co-Founder & Independent Director 1955
Mr. Scott L. Burrows CFO & Principal Accounting Officer 1977
Dr. David W. Osborne Ph.D. Chief Technical Officer 1961
Dr. Patrick E. Burnett M.D., Ph.D. Sr. VP & Chief Medical Officer 1972
Mr. Matthew Richard Moore Sr. VP & Chief Bus. Officer 1974
Ms. Patricia A. Turney Sr. VP of Operations 1967
Mr. Eric McIntyre Head of Investor Relations NA
Ms. Courtney Barton VP and Chief Compliance Officer & Privacy Officer 1983
Mr. Masaru Matsuda Esq., J.D. Sr. VP, Gen. Counsel & Corp. Sec. 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.